普洛藥業(000739.SZ)捐贈10萬盒“百士欣”烏苯美司膠囊用於疫情防控
格隆匯2月20日丨普洛藥業(000739.SZ)公佈,面對新型冠狀病毒肺炎疫情防控的嚴峻形勢,公司作為國內醫藥上市公司,積極投身疫情防控工作,在切實做好企業自身疫情防控工作,維護公司正常生產經營的同時,積極履行上市公司社會責任。現通過湖北省紅十字會向奮戰在湖北疫情防控一線的醫護人員捐贈“百士欣”烏苯美司膠囊10萬盒,價值約人民幣1100萬元。
公司生產的國家二類新藥“百士欣”烏苯美司膠囊,作為APN拮抗劑,在臨牀試驗和大量的臨牀使用中,可以快速增加20-30%的淋巴細胞總計數,增加CD4+T細胞,從而顯著提升人體免疫力,降低感染機率。同時,在臨牀使用中安全性很高,且副反應機率低於1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.